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Abstract
Background: Migraine is a common disorder that is highly co-morbid with psychopathological conditions such as
depression and anxiety. Despite the extensive research and availability of treatment, migraine remains under-
recognised and undertreated. The aim of this study was to design a short and practical screening tool to identify
migraine for clinical and research purposes.
Methods: The structured migraine interview (SMI) based on the International Classification of Headache Disorders
(ICHD) criteria was used in a clinical setting of headache sufferers and compared to clinical diagnosis by headache
specialist. In addition to the validating characteristics of the interview different methods of administration were also
tested.
Results: The SMI has high sensitivity (0.87) and modest specificity (0.58) when compared to headache specialist’s
clinical diagnosis.
Conclusions: Our study demonstrated that a structured interview based on the ICHD criteria is a useful and valid
tool to identify migraine in research settings and to a limited extent in clinical settings, and could be used in
studies on large samples where clinical interviews are less practical.
Background
It has been estimated that migraine is the second most
prevalent brain disorder after anxiety, affecting nearly 41
million adult Europeans [1]. In a general population
sample, 60% of migraine sufferers were not aware that
they had migraine [2]. Only a small fraction of migraine
sufferers were diagnosed. In one study, a diagnosis of
migraine was only made for 41% of women and 29% of
men who suffer with migraine headaches [3].
An even smaller fraction received treatment [4] with a
very low percentage using prophylactic migraine therapy
[5]. Even if they do seek help, almost 80% of patients
with active migraine have no medical follow up [2].
Despite having effective treatment to relieve symptoms
of acute migraine attacks such as triptans, the response
rate to triptans varied from 44-70% and only Sumatrip-
tan s.c. administration achieved 80% response rate [6].
In addition, triptans are expensive and not all patients
have access to them. In a large population study of US
households, only 20% of migraine sufferers used pre-
scription treatment for acute migraine [7]. Migraine
attacks were reported to occur at a rate of more than 3
per month in 31.3% of migraine sufferers and over half
of migraine sufferers reported severe impairment. Over
a quarter met the criteria for preventative treatment,
however only 13% reported current use of such treat-
ment [8].
Like psychiatric disorders, there are no known biologi-
cal markers to identify migraine and the diagnosis is lar-
gely clinical, based on careful history taking and the
absence of significant signs on physical examination. To
avoid inconsistency and lack of agreement between clin-
icians and researchers, a structured and reliable method
to define clinical syndromes and phenotypes such as
depression and migraine, is needed to improve diagnos-
tic accuracy [9].
In order to identify migraine in a systematic fashion,
the International Headache Society (IHS) produced
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any medium, provided the original work is properly cited.diagnostic criteria and classification system for primary
headache disorders including migraine [10]. This pro-
vided a method for targeting a group of headache
patients in need of care [11] to ensure accurate identifi-
cation and a measurable way to assess outcome.
T h em a j o r i t yo fm i g r a i n ee p i d e m i o l o g i c a ls t u d i e s
based on these criteria have provided a degree of har-
mony in identifying migraine. Nevertheless, the meth-
odologies of case identification diverge greatly. Most
epidemiological studies were conducted in the western
world and showed migraine lifetime prevalence ranging
from 10 - 28% [12][13][14][15][16][17][18]. The preva-
lence of migraine was much lower for a Japanese popu-
lation (6%) [19]. More recent review of migraine
prevalence studies worldwide (Africa, Asia, Australia,
Europe, North America, Central and South America)
that have been published since the introduction of the
second edition of the International Classification of
Headache Disorders (ICHD) [10] showed an average
rate of 11% [20]. Although neurological and psychiatric
disorders comprise only 1.4% of all deaths, they account
for a remarkable 28% of all years of life lived with a dis-
ability [21]. The World Health Organization (WHO)
estimated that there are 3000 migraine attacks occurring
daily for every million population [22]. The WHO con-
sidered the disability from living with a day of a
migraine attack to be similar to living with a day of
quadriplegia [21].
Recognition of migraine is therefore important to
reduce the symptoms’ impact on patients as well as
improving prognosis and associated psychiatric comor-
bidity. Migraine has been shown consistently to be asso-
ciated with psychopathology such as depression [23] and
anxiety [24] however; migraine is seldom screened for in
psychiatric populations andb a r r i e r sc o n t i n u et oe x i s t
that prevent the identification of migraine in different
patients particularly in psychiatric populations.
The aim of the current study was to design a short
and practical screening tool to identify migraine in set-
tings where clinical interviews are not possible or practi-
cal such as large population studies and clinical practice
where neurological expertise is limited.
In this study we report the validation of The Struc-
tured Migraine Interview (SMI) based on the ICHD cri-
teria [10]. The purpose of the interview was to establish
a lifetime ever diagnosis of migraine.
Methods
The migraine interview wasd e s i g n e dt oa n s w e rt h e
question of “did this person suffer from migraine at any
time in his/her life?” Thus, questions were formulated
to cover the individual items in the ICHD criteria, in
t h ef o r mo fab r i e f1 0q u e s t i o ns t r u c t u r e di n t e r v i e w .I n
addition to administration by an interviewer the
questions could also be answered by self-report. As well
as the presence of headache, enquiry was made about
severity, frequency, duration, location, character, aura
and other accompanying symptoms. The study was
approved by the local ethics committee. The interview
was then pilot tested on a small group of university staff
members (n = 20, 70% were female, mean age 37.9
years, range 26-52). Participants were asked to comment
on the relevance of the questions and any difficulties
they had in completing the questionnaire. This informa-
tion was then used to modify the interview into its final
version (Additional file 1).
The average time required to complete the questions
(by self report) was 5 minutes (range 3-10 minutes).
The SMI consisted of 10 questions to yield the diagnosis
of migraine with aura or migraine without aura. In addi-
tion the SMI included questions to distinguish probable
migraine and non-migraine recurrent headaches.
The criteria for diagnosing migraine (ICHD) were as
follows:
1. Migraine with aura (MA). At least 2 episodes of
aura symptoms including visual disturbances prior
to the onset of headache and fulfilling criteria for
migraine, as in migraine without aura below.
2 .M i g r a i n ew i t h o u ta u r a( M O ) .A tl e a s t5e p i s o d e s
of moderate to severe headache with all of the
following:
a) Pulsating or one-sided headache
b) Associated with nausea and/or vomiting and/
or hypersensitivity to light or sound
c) Headache exacerbated by movement or similar
physical activity
d) Headache lasting 4-72 hours
3. Probable Migraine (MP). At least 5 episodes of
moderate to severe headache with only 3 of the fea-
tures listed above under 2a-d.
4. Other headaches (OH). Recurrent headaches that
do not fulfil the criteria for any form of migraine.
5. No recurrent headaches (NH).
The responses from the SMI were then scored using
a computerized coding algorithm to generate the
migraine diagnoses. The diagnosis of migraine with
aura here is based on having the diagnostic features of
m i g r a i n ew i t h o u ta u r at h a tm u s ti n c l u d ea tl e a s t5
attacks in a lifetime. In addition for the diagnosis of
migraine with aura, there must be at least 2 attacks
accompanied by aura symptoms as in question 4
(Additional file 1). In Additional file 1, question 3 we
asked about hypersensitivity to sound or light while
the ICHD criteria was worded to say “moderate to
severe headache accompanied by hypersensitivity to
sound AND light” This question is unlikely to over-
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migraine tend to under report these symptoms on rou-
tine questioning [25]. In addition each symptom alone
is similarly correlated with migraine headache [26]. On
the other hand, sensitivity to sound and light assessed
alone was also found to be different predictors of
migraine when compared to the gold standard (clinical
diagnosis). This led to selecting only one (photosensi-
tivity) for use in screening questionnaires [27]. It was
also reported that the use of self-administered head-
ache symptoms in a diary led to under-reporting of
accompanying symptoms such as photophobia and
phonophobia [28]. The use of this question 3 is there-
fore unlikely to have led to diagnosing MO in persons
not fulfilling the criteria for MO. In question 7 (Addi-
tional file 1) we added “certain foods” as a result of
the initial pilot were it was commonly reported that
certain foods such as chocolate have triggered head-
ache. This item was not considered as part of the diag-
nostic criteria. We also added question 10 that is not
part of the ICHD criteria for 2 reasons. 1
st to identify
any causes for headache to distinguish primary from
secondary headaches and 2
nd to identify the proportion
of people who were identified as migraine sufferers
and if they actually knew that they had migraine.
Recruitment of study subjects from the City of
London Migraine Clinic for the validity and
reliability studies
The City of London Migraine Clinic is a research centre
and outpatient service for people with migraine and
other headaches with 30 years of experience in treating
headache disorders. Two of medical staff working in the
clinic agreed to participate in the validity and reliability
study of the SMI. The clinic receives referrals mainly
from general practice but also from tertiary care
throughout the UK. Patients attending the clinic were
referred to the clinic because they suffered from signifi-
cant headaches that were not managed by general prac-
tice and other health care providers. These patients
were not all migraine sufferers but had other types of
headaches. All patients who were registered with the
clinic at the time of the study conduction (2003) were
considered as potential study participants. In order to
maintain confidentiality, information sheets and consent
forms about the study, as well and the SMI question-
naires were sent directly by the clinic to their patients.
Subjects who agreed to participate signed a consent
form, and completed the SMI, returning both directly to
the researcher (ZS) using the stamped addressed envel-
opes provided.
The clinic mailed out information about the study
(December 2003) to their patients along with consent
forms asking interested patients to take part in the
study. Subjects who were willing to participate provided
written informed consent and completed the SMI as
well as demographic details.
The migraine diagnosis based on the SMI was com-
pared with the migraine diagnosis assigned to the sub-
jects by headache specialists. Migraine remains a clinical
diagnosis and the clinical diagnosis is considered the
“gold standard”. Therefore in order to test the validity of
the SMI compared to the diagnosis obtained from a
headache specialist, a sub sample was selected. Two
hundred subjects were randomly selected from migraine
clinic attendees’ respondents. The list of 200 subjects
was then sent to the Migraine Clinic headache specialist
to provide the clinical diagnoses. For practical reasons
(time and resources available at the time of the study
conduct) we selected a random sample form the original
sample to test for the validity of the questionnaire. The
selection ensured an equal opportunity for each partici-
pant to be selected by generating a random list of 200
study ID numbers that were assigned to participants
arbitrary to conceal subjects’ identity. This random and
blind selection ensured a representative sample to be
selected from the original study participants.
The study also tested the use of the SMI comparing
face to face interview with an interviewer administered
telephone interview. Twenty randomly selected subjects
from the Depression Case Control migraine study [23]
who had been interviewed face to face to complete the
SMI were re-interviewed by telephone to obtain a life
time diagnosis of migraine. The time between the face
to face and telephone interviews was a mean of 2.5
years (range 1-4). Fifty subjects were randomly selected
by the senior author blinded to migraine status in order
to generate at least 20 subjects for comparison.
The data were entered into SPSS statistical package
version 16 [29]. Statistical analysis was performed to
estimate sensitivity and specificity of the SMI. Bivariate
correlations were used to estimate the strength and
direction of associations between SMI diagnoses, and
the use of migraine pharmacological treatment and self
reported migraine diagnoses.
Results
Six hundred and forty six subjects completed the study
data forms between December 2003 and April 2004.
Demographic details are described in Table 1. Women
represented the majority of subjects (82%) and the mean
age of the study subjects was 48.6 years (SD 11.6).
Seventy three percent of participants reported having
migraine and 60% were receiving migraine pharmacolo-
gical treatment. Just over half of participants were also
taking over the counter analgesics. According to the
SMI, 54.2% of subjects were diagnosed with migraine
(with or without aura) in this sample.
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Normality showed that the data distribution violated the
assumption of normality p = 0.012). The diagnosis
obtained by the SMI was significantly correlated with
self-reported migraine (Spearman’s rho = 0.16, p =
0.001). The SMI diagnosis was also significantly asso-
ciated with taking migraine treatment (Spearman’sr h o
= 0.35, p < 0.0001) and analgesics use (Spearman’sr h o
= 0.12, p = 0.003).
Two hundred subjects were randomly selected (by
senior author AF) from the migraine probands data base
maintaining blindness to their migraine diagnoses.
These subjects were then sent to the Migraine Clinic
headache specialist to provide the clinical diagnoses.
The headache specialist was able to verify 170 (85%)
subjects’ diagnoses. The clinical diagnosis included only
3 categories: migraine with aura 30.3%, migraine without
aura 65.2% and other non-migraine headache 4.5%. In
addition many cases of migraine with aura also had
migraine without aura. There were no cases of probable
migraine according to the clinical diagnosis. Therefore
we combined the clinical diagnostic categories into
migraine to include migraine with and without aura and
non-migraine headaches. We designed the questionnaire
with different types of migraine (with aura, without aura
and probable migraine) in mind and we have included
the ICHD criteria pertaining to the different types at the
2-digit level. However based on the clinical diagnosis,
there were no cases of probable migraine diagnosed and
most cases of migraine witha u r aw e r ea l s od i a g n o s e d
with migraine without aura that is not uncommon in
clinical settings. In addition, to avoid making the cells
numbers fewer we decided to include all cases of
migraine with and without aura and probable migraine
as migraine. The sensitivity was 0.87 and specificity was
0.58 (Table 2). In addition, the misclassification rate was
0.15, positive predictive value was 0.97, and negative
predictive value was 0.26.
With respect to comparing the face to face interview
with an interviewer administered SMI telephone inter-
view, from the 50 subjects selected; nine subjects were
not contactable (disconnected telephone numbers or no
longer residing at this address), one subject had died
since participation in the original study and three sub-
jects did not consent for future contact therefore were
not contacted. Once 20 completed telephone interviews
h a db e e no b t a i n e dn of u r t h e rsubjects were contacted.
Hence the final 17 subjects selected were not contacted
and their data were excluded from the analysis. The
spearman’s rho correlation coefficient comparing the
face-to-face and telephone interview methods for com-
pleting the SMI was 0.84, (p < 0.0001). Kappa statistic
was 0.82 (p < 0.0001).
Discussion
The migraine diagnosis generated by the structured
migraine interview was positively associated with self
reported migraine and receiving treatment for migraine
in a clinical sample of headache sufferers attending a
specialized clinic. It has been suggested that a disorder
associated with impairment or requiring treatment is
usually associated with good reliability of recall [30].
This may also reflect that the patients attending a spe-
cialized clinic for their headache represent the extreme
end of severity and the associated impairment that they
do require such specialist intervention. We can argue
that these patients are highly selected with increased
awareness about their headaches compared to general
population samples. In addition, the retrospective collec-
tion of headache data has the disadvantage of recall bias
that may lead to remembering the most severe episodes
of headaches thus providing one extreme of the head-
ache spectrum. Nonetheless the SMI was able to detect
significant number of migraine sufferers in this sample.
However, it cannot be concluded on the basis of the
current study that self reported migraine or the use of
Table 1 Demographic data of study participants (n = 646)
Ethnicity Caucasian Indian Black
96% 2% 2%
Education Post Graduate University National diploma/Certificate O or A Level CSE No qualification
5.7% 9.8% 2.7% 55.6% 17.5% 8.8%
Occupation Professional Technical/Secretarial Full time Student Home making Self employed Unemployed
51.2% 21.4 1.7% 11.9% 7.1% 6.7%
Table 2 SMI vs. headache specialist’s clinical diagnoses
“gold standard”
Clinical Diagnoses Total
SMI Diagnoses Migraine No Migraine
Migraine 138 (a) 5 (b) 143
No Migraine 20 (c) 7 (d) 27
Total 158 12 170
Sensitivity: a/(a+c) = 138/138+20 = 138/158 = 0.87
Specificity: d/(b+d) = 7/5+7 = 7/12 = 0.58
Misclassification rate: b+c/(a+b+c+d) = 5+20/(138+5+20+7) = 25/170 = 0.15
Positive predictive value: a/(a+b) = 138/(138+5) = 138/143 = 0.97
Negative predictive value: d/(c+d) = 7/(20+7) = 7/27 = 0.26
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migraine.
T h er e s u l t so fv a l i d i t yt e s t i n go ft h eS M Is h o wt h a t
compared to clinical diagnos i st h eS M Ii sh i g h l ys e n s i -
tive (0.87) but less specific (0.58) in identifying migraine
cases. This could be because almost all subjects referred
to the migraine clinic (by definition) suffered from head-
aches so the validity sample was unbalanced by lack of
subjects without headache. In addition, traditionally clin-
ical diagnosis is known to be more liberal compared to
structured criteria that were aimed at research case
identification. In clinical practice some patients do not
necessarily “fit in” to any classification system and the
majority may have a combination of symptoms that
need management regardless of the exact diagnosis
especially for disorders such as migraine that are recur-
rent and disabling in nature. The difference between
clinical and research diagnoses is therefore expected and
in keeping with conventional practice. The questionnaire
method, although restrictive,i ti ss u i t a b l et oi d e n t i f y
true cases of migraine that is paramount to research
methods. Indeed, we have used the SMI in two large
studies of depression case-control [23] where migraine
prevalence in depressed subjects (n = 1259) was found
significantly higher than psychiatrically healthy controls
(n = 851) and a depression sibpair study (from 495
families, total subjects = 1052) where siblings concor-
dant for depression showed positive correlations for
migraine [31].
Although the numbers in the validity study are mod-
est, we believe that the result sa r ea b l et od e m o n s t r a t e
specificity and sensitivity, and are in keeping with larger
sample sizes [32]. A previous study employing similar
methodology with a modest sample size of 61 headache
sufferers concluded that a combination of using a diary
and a clinical interviewing was more effective than
either method alone [33]. In addition to the 170 indivi-
duals whose diagnoses were confirmed by the headache
specialist in this study, 646 subjects who were attending
the headache clinic and received formal diagnoses for
their headaches were tested using the SMI. Even though
the reported diagnoses were by self-report, the diagnoses
obtained by the SMI were significantly correlated with
self-reported migraine (Spearman’s rho = 0.16, p =
0.001). In a study of self recognition of migraine, Lipton
e ta l[ 3 4 ]n o t e dt h a ti n d i v i d u a l sw h or e p o r t e dt h a tt h e y
had migraine were 3 times more likely to meet the
ICHD criteria for migraine.
A self administered questionnaire was tested in 713
individuals and compared to clinical interviews. Ninety
three subjects were identified as having migraine in clin-
ical interviews and 94 subjects classified as having
migraine using the questionnaire method (a self admi-
nistered questionnaire based on the ICHD 1988 criteria)
[32]. The sensitivity of a self administered questionnaire
in Rasmussen and colleagues study was lower than the
SMI (0.51 compared to 0.87) with high specificity 0.92.
The study using McNemar test for symmetry in a 2 × 2
table similar to table 2 found that the two types of
inconsistencies (false positive by the questionnaire “b”
and false positive by the clinical interview “c” were
equally common (c
2 =0 . 0 1 ,d f=1 ,p<0 . 9 ) .T h e
authors concluded that the use of self administered
questionnaire was less sensitive but highly specific,
therefore the use of self administered questionnaire in
the clinical settings will lead to under-reporting of true
cases of migraine [32]. Other studies have also shown
significant sensitivity and specificity of self administered
questionnaire based on the ICHD criteria for the diag-
nosis of migraine compared to clinical interview. In a
German study of self administered headache question-
naire based on ICHD in a clinical setting validated
against clinical interview, the sensitivity was 0.73 and
specificity 0.96 [35]. In a Danish study of self adminis-
tered headache questionnaire based on ICHD, which
included 56 questions about headache and accompany-
ing symptoms in a clinical sample, the sensitivity was
0.63 and specificity 0.92 for the over all diagnosis of
migraine with and without aura [36]. Better validity
parameters were achieved by looking at each type of
migraine separately [36]. Other studies showed higher
sensitivity (0.89) and lower specificity (0.79) of nurse
administered (with no experience in headache disorders)
migraine questionnaire based on the ICHD criteria and
designed for use in clinical practice compared to a clini-
cal interview by a headache specialist [37] reflecting the
over inclusive nature of clinical diagnosis versus the nar-
row more stricter classification based diagnosis. A
shorter self administered screening questionnaire based
on 3 questions had also shown good sensitivity (0.81)
and moderate specificity (0.75) but was unable to distin-
guish different types of migraine [27]. Our study
demonstrated that the use of a structured interview (self
rated or interviewer administered) based on the ICHD
criteria is a useful and valid tool to use in research for
the identification of migraine in large samples where
clinical interviews are less practical. However, a ques-
tionnaire method can not replace clinical interviews
when possible.
In this study, we have found that face-to-face inter-
views and telephone interviews showed significant corre-
lations. However, the duration between the two
interviews is relatively long (mean 2.5 years) to draw sig-
nificant conclusions as during this period subjects may
developed new onset of migraine or have recovered and
forgot to report previous history of migraine. In addition
t h es a m p l es i z ei nt h i sp a r to ft h es t u d yi sm o d e s t( n=
20) to produce firm conclusions. It was however
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SMI as a tool for telephone interviewing. It can also be
argued that the repeatability of the original findings of
migraine were probably accounted for by learned
answers in that the subjects knew the questions and
gave similar answers to the original questions. This sce-
nario is unlikely given that the agreement was not 100%
and the subjects were re-interviewed at various times.
Studies of the validity of telephone interviews in com-
parison to face to face interviews for psychiatric disor-
ders [38,39] and other medical conditions using
different scales [40] have shown substantial agreement
suggesting telephone interviews to be valuable tools in
conducting research.
Other methods of migraine diagnosis were also tested
such as the use of a headache diary [28]. The Copenha-
gen group employed similar study design to the SMI
based on the IHCD 1988 criteria. The study included 61
participants from a specialized headache centre. The
sensitivity of the headache diary for migraine with out
aura was excellent at 0.94; the specificity however was
modest at 0.50. For migraine with aura the sensitivity
and specificity were 0.73 and 0.72 respectively. The
authors concluded that the use of the diary should be
supplemented by a clinical interview to improve accu-
racy [28]. The SMI had a sensitivity of 0.87 and specifi-
city of 0.58 indicating a useful instrument in identifying
migraine in settings where headache expertise is not
available.
Conclusions
The use of a questionnaire based on the ICHD criteria
for migraine is shown to be a valid and simple method
to use in diagnosing migraine in research settings and
with caution in clinical settings due to limited
specificity.
Additional file 1: Structured Migraine Interview. The file contains the
structured migraine interview ten questions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2377-10-7-
S1.DOC]
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